{
  "docId": "019de516-01ce-701d-bd9b-acac15fa9fab",
  "docSlug": "a13be9775a99db49a0c5c2ac3ee2ea88",
  "documentTitle": "Oculis | Investor Conference Presentation Deck | 39 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 39,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "propose_solution",
  "function": "propose_solution",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de516-01ce-701d-bd9b-acac15fa9fab/26",
  "deckHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab",
  "deckJsonHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab.json",
  "deckAnchorHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.52,
        "w": 0.47,
        "x": 0.47,
        "y": 0.29
      },
      "kind": "image",
      "text": "IgG, Fab, scFv* (OCS-02) antibody fragments with molecular weights 149 kDa, 48 kDa, and 26 kDa respectively, showing regions that bind to neutralize TNFα.",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c216dbd6-6845-4f0a-9179-688058b9341f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.404,
        "x": 0.046,
        "y": 0.795
      },
      "kind": "list",
      "text": "Proprietary genetic biomarker Associated with OCS-02 response highlighting opportunity for a precision treatment in DED",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "138a3609-abda-4c98-ac9f-18a6d8581877",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.404,
        "x": 0.046,
        "y": 0.635
      },
      "kind": "list",
      "text": "Enhanced ocular penetration Lower molecular weight, enhanced ocular penetration and higher concentration",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64012581-5cc8-4a49-9674-17bc0bdd3406",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.404,
        "x": 0.046,
        "y": 0.445
      },
      "kind": "list",
      "text": "Clinically proven MoA Anti-inflammation and anti-necrosis MoA approved as systemic treatment for ocular disease and with transformative impact in other areas",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71f58152-2e73-4d3b-b561-8cc04fb35c7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.404,
        "x": 0.046,
        "y": 0.315
      },
      "kind": "list",
      "text": "OCS-02 is an anti-TNFα antibody fragment formulation with potential to become the first approved topical biologic for DED",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2aafaff-e8f7-47d7-9f79-b3a9babb7d2e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.018,
        "w": 0.018,
        "x": 0.958,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "26",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5e9f8c6-9ccb-44ed-b3c1-4d6c1870740b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.83,
        "x": 0.026,
        "y": 0.088
      },
      "kind": "title",
      "text": "Clinically proven MoA with potential transformative impact in Ocular Inflammatory Diseases",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a2e6e130-a5a8-413e-b4fa-803d0e7ff69f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.69,
        "x": 0.026,
        "y": 0.05
      },
      "kind": "title",
      "text": "OCS-02 | First Topical Treatment Candidate for DED",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "345b195a-6589-4a04-8a90-78ab6c0dd549",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "db8952f2-59e3-4a9a-917b-9a76cede2f35",
      "evidence": "The slide uses action titles to present information about the product, including 'Clinically proven MoA' and 'Transformative impact'.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 39,
      "from": 25,
      "beatId": "6cce666b-f795-4a3e-a589-afe2a7266ece",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 25-39 discuss OCS-02, OCS-05, and the track record of efficient capital deployment.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}